CG Labz
Peptide Library / Growth Hormone / Performance

CJC-1295 with DAC

GRF analog + Drug Affinity Complex

CJC-1295 with DAC Research Protocol

Complete Research Guide 4 min read2 peer-reviewed references

Quickstart Overview

CJC-1295 with DAC is a GHRH analog bearing a Drug Affinity Complex (a maleimidopropionic linker) that covalently binds serum albumin, extending its half-life to roughly 6–8 days. Unlike the no-DAC form it produces sustained GH/IGF-1 elevation rather than discrete pulses.

Reconstitution
Add 2.0 mL bacteriostatic water to a 2–5 mg vial
Literature Range
1–2 mg weekly
Half-life
~6–8 days (albumin-bound)
Measuring Reference
At 2.5 mg/mL: 1 mg = 0.4 mL = 40 units
Frequency
1–2× weekly
Route (studies)
Subcutaneous

Scientific Data

Molecular Formula
—
Molecular Weight
3647.16 Da
Sequence
Mod GRF(1-29) + maleimidopropionic DAC
Sequence Length
27
CAS
Research compound
Peptide Family
GHRH analog
Half-life
Refer to published literature
Solubility
Bacteriostatic water, sterile saline
Storage
Lyophilized: -20°C. Reconstituted: 2–8°C, use within 2–4 weeks.
Appearance
White lyophilized powder
Standard: 5 mg vial · 2 mL diluent

Dosing & Reconstitution Guide

Interactive Reconstitution
Adjust vial size, diluent and target dose. Results update live.
Full Precision Calculator →
Concentration
2.50 mg/mL
Draw Volume
0.400 mL
Syringe Units
40.0 U
Doses / Vial
5

Units assume a U-100 insulin syringe (100 units = 1 mL). DAC gives a 6–8 day half-life and continuous GH elevation, not pulses.

Frequency: 1–2× weekly

Reconstitution Steps

  1. 1Allow the lyophilized vial and bacteriostatic water to reach room temperature (~15 min).
  2. 2Swab both vial stoppers with a fresh 70% isopropyl alcohol pad and let them dry.
  3. 3Draw 2.0 mL of bacteriostatic water into a mixing syringe.
  4. 4Insert at an angle and let the water run slowly down the glass wall — never directly onto the powder.
  5. 5Gently swirl (do not shake) until the solution is completely clear.
  6. 6Label with date and concentration (mg/mL) and refrigerate at 2–8 °C immediately.

Supplies Needed

Planning example for a 12-week protocol at approximately 300 mcg per day.

Peptide (5 mg vials)
Estimate vials from total mass: 300 mcg/day × 84 days.
Bacteriostatic Water
One 10–30 mL vial typically covers a full cycle.
Insulin Syringes (U-100)
One per administration (29–31 G, 0.3–0.5 mL).
Alcohol Swabs
Two per administration (vial + site).
Sharps Container
Required for safe disposal.

Protocol Overview

Goal
Model sustained GHRH-receptor stimulation with weekly dosing.
Schedule
1–2× weekly, 8–16 weeks.
Dose Range
1–2 mg/week.

Dosing Protocol

Standard
1–2 mg once or twice weekly
Frequency
1–2× weekly
Target
2 mg/week typical
Cycle Length
8–16 weeks
Timing
Time of day less critical due to long half-life
Route
Subcutaneous

Storage Instructions

Lyophilized
−20 °C long term (18–24 months); stable at room temperature for short transit.
Reconstituted
2–8 °C refrigerated; use within 4 weeks.
Light
Protect from direct light; keep in the original carton.
Freeze/Thaw
Avoid repeat freeze–thaw cycles after reconstitution.

Important Notes

  • Continuous GH elevation (loss of pulsatility) is the key mechanistic trade-off vs no-DAC.
  • Monitor IGF-1 and glucose in extended protocols.

How This Works

The four GHRH substitutions resist enzymatic degradation while the DAC linker binds circulating albumin, shielding the peptide from clearance. The result is a 'GH bleed' — continuously elevated GH and IGF-1 over days rather than the sharp pulses of Mod GRF 1-29. It acts on the GHRH receptor pathway and is therefore additive with ghrelin-receptor agonists.

Potential Benefits & Side Effects

Reported in research
  • Sustained elevation of GH and IGF-1 over days
  • Convenient 1–2× weekly dosing
  • Additive with ghrelin agonists (e.g. ipamorelin)
  • Improved recovery and body-composition markers in studies
Possible considerations
  • Water retention (more pronounced than no-DAC)
  • Flushing and head-rush post-dose
  • Injection-site reactions
  • Carpal-tunnel-like symptoms at higher doses
  • Loss of GH pulsatility is a mechanistic trade-off

Lifestyle Factors

  • Adequate hydration and 7–9 h of sleep are standard controls in most research protocols.
  • Consistent dose timing improves the reliability of any self-tracked endpoints.
  • Maintain a clean, sterile workflow for every draw to avoid contamination.

Injection Technique

  1. 1Wash hands, then prep the vial top and the target site with separate alcohol swabs.
  2. 2Pinch a subcutaneous skin fold (abdomen, ~2 inches from the navel) and insert at 45–90°.
  3. 3Depress the plunger slowly over 3–5 seconds, hold 5 seconds, then withdraw.
  4. 4Rotate sites each administration and dispose of the syringe in a sharps container.

Frequently Asked Questions

Third-party HPLC testing

CG Labz Verified Batches

No published batches yet.

Research Disclaimer

All compounds are supplied strictly for laboratory research. Dosing figures below summarize ranges reported in published preclinical and clinical literature for reference purposes only. CG Labz does not provide medical advice or individualized dosing recommendations.

Peer-reviewed literature

References

  1. [1] Endocrinology
    Jetté L. et al. hGRF1-29-albumin bioconjugates: CJC-1295 as a long-lasting GRF analog.
    View Source
  2. [2] J Clin Endocrinol Metab
    Teichman S.L. et al. Prolonged stimulation of GH and IGF-1 by CJC-1295.
    View Source